Ergosterol Biosynthesis Inhibition & Mycological Clearance
Third-generation imidazole and allylamine therapeutics designed for rapid fungicidal action against dermatophytes, yeasts, and moulds with sustained skin retention.

Eberconazole 1% · Ketoconazole 2% · Zinc Pyrithione · Luliconazole
Each product is manufactured in compliance with international cGMP standards and verified by HPLC assay.
DermaGenesis has therapeutic dossiers currently under active phase trial and stability testing in this discipline. Registered dermatologists can contact Medical Affairs for pipeline monograph access.
Eberconazole and Ketoconazole inhibit fungal 14α-demethylase, disrupting ergosterol synthesis and causing lethal cell wall permeability in Trichophyton and Malassezia species with zero host cell cytotoxicity.
Broad-spectrum fungicidal activity clearing dermatophyte infections within 14 days.
Suppresses Malassezia yeast colonization, relieving redness and greasy scales.
Rapidly eliminates Candida albicans in warm, intertriginous skin folds.
Dual antifungal and intrinsic anti-inflammatory action resolves itching within 48 hours.
Always continue therapy for 10-14 days after physical symptoms vanish to eradicate fungal spores.
Ensure treatment areas are completely dried with clean towels before topical application.
Wear loose-fitting breathable cotton clothing to prevent moisture build-up during treatment.